SEC Comment Letter for Greenwich LifeSciences, Inc. (GLSI) (CIK 0001799788) (GLSI) — Mar 31, 2022
Greenwich LifeSciences, Inc. (GLSI) (CIK 0001799788)
Date: March 31, 2022 · CIK: 0001799788 · Accession: 0000000000-22-003518
AI Filing Summary & Sentiment
File numbers found in text: 333-263855
Letter
United States securities and exchange commission logo March 31, 2022 Snehal Patel Chief Executive Officer Greenwich LifeSciences, Inc. 3992 Bluebonnet Dr., Building 14 Stafford, TX 77477 Re:Greenwich LifeSciences, Inc. Registration Statement on Form S-3 Filed March 25, 2022 File No. 333-263855 Dear Mr. Patel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Gary Guttenberg at (202) 551-6477 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey Fessler
Show Raw Text
United States securities and exchange commission logo
March 31, 2022
Snehal Patel
Chief Executive Officer
Greenwich LifeSciences, Inc.
3992 Bluebonnet Dr., Building 14
Stafford, TX 77477
Re:Greenwich LifeSciences, Inc.
Registration Statement on Form S-3
Filed March 25, 2022
File No. 333-263855
Dear Mr. Patel:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Gary Guttenberg at (202) 551-6477 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeffrey Fessler